Zidesamtinib Tablets 25 mg, 100 mg Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 25 mg, 100 mg
Reference Brands: Jideytro
Category: Oncology Cancer Care
Zidesamtinib (Jideytro, Nuvalent) is a ROS1-selective kinase inhibitor for ROS1-positive non-small cell lung cancer after a previous ROS1 inhibitor, approved by the US FDA in July 2026. PharmaTradz handles enquiries for authorised supply of the originator product (named-patient and import-permit orders), and connects developers, API makers and licensees preparing for patent expiry.
Manufacture or export Zidesamtinib Tablets? List it or send an offer →
Product Description:
Zidesamtinib blocks the ROS1 kinase, including the G2032R resistance mutation that stops earlier drugs such as crizotinib and entrectinib from working. It crosses into the brain, where ROS1-positive lung cancer often spreads, and it was designed not to inhibit the related TRK kinases. TRK inhibition causes the dizziness, weight gain and falls seen with some other ROS1 drugs.
The US FDA approved zidesamtinib as Jideytro in July 2026 for adults with ROS1-positive, locally advanced or metastatic non-small cell lung cancer previously treated with a ROS1 tyrosine kinase inhibitor. It is supplied as 25 mg and 100 mg tablets.
Sourcing and licensing notes. Zidesamtinib is patented and made only by Nuvalent; there is no generic. Other ROS1 options on PharmaTradz include crizotinib, entrectinib, repotrectinib and taletrectinib. We handle enquiries for authorised supply of Jideytro and connect developers and licensees interested in the molecule ahead of patent expiry.
How Zidesamtinib Tablets is supplied today, and licensing ahead of patent expiry
Where zidesamtinib is approved
Checked 3 Oct 2026| Market | Status | Brand · regulator · date |
|---|---|---|
| United States | Approved | Jideytro · FDA · Jul 2026 |
| Generic / biosimilar | None | None approved as of the check date |
Not approved in your country? A hospital or doctor can often still import it for a named patient, through a special-access, import-permit or compassionate-use route. We confirm which route applies in your country and the documents needed before quoting. Ask about named-patient supply →
Frequently Asked Questions
ROS1-positive advanced non-small cell lung cancer in adults already treated with a ROS1 inhibitor.
Jideytro, from Nuvalent. The US FDA approved it in July 2026.
Yes. It was designed to block ROS1 with the G2032R resistance mutation and to reach the brain.
No. It is patented. We handle authorised-supply enquiries and connect developers and licensees preparing for patent expiry.
Related Products
Sunvozertinib Tablets
Strength:
150 mg, 200 mg
Form: Tablets
Reference Brands: Zegfrovy
View DetailsSonrotoclax Tablets
Strength:
1 mg, 5 mg, 20 mg, 80 mg
Form: Tablets
Reference Brands: Beqalzi
View DetailsDatopotamab Deruxtecan for Injection
Strength:
100 mg
Form: Lyophilised powder vial (IV infusion)
Reference Brands: Datroway
View DetailsTelisotuzumab Vedotin for Injection
Strength:
20 mg, 100 mg
Form: Lyophilised powder vial (IV infusion)
Reference Brands: Emrelis
View DetailsZanidatamab for Injection
Strength:
300 mg
Form: Lyophilised powder vial (IV infusion)
Reference Brands: Ziihera
View DetailsPivekimab Sunirine for Injection
Strength:
2 mg
Form: Lyophilised powder vial (IV infusion)
Reference Brands: Decnupaz
View DetailsUsually answered within 48 hours | GMP documents shared before you commit
